osteoporotic fracture is a major cause of morbidity in patients with systemic lupus erythematosus (SLe). Mice lacking fc gamma receptor iib (FcγRIIB) spontaneously develop lupus-like disease or SLe at 6-month-old. The aim of this study was to investigate whether FcγRIIB deletion induces osteopenia. μct analysis indicated that deleting FcγRIIB did not affect cancellous bone microarchitecture in 3-month-old mice in which SLE had not yet developed. However, 6-and 10-month-old FcγRIIB −/− males that developed an SLe-like phenotype were osteopenic and FcγRIIB deletion resulted in decreased cancellous bone volume. Histomorphometry confirmed a significant decrease in cancellous bone volume in 6-and 10-month-old FcγRIIB −/− males. the osteoclast number was increased without any change in osteoblast number. In vitro assays indicated that deleting FcγRIIB increased osteoclast differentiation while alkaline phosphatase activity and mineralization were unaltered. These changes were associated with increases in steady-state mRnA levels for the osteoclast marker genes Trap and Ctsk. Moreover, FcγRIIB −/− mice had higher level of serum tnfα, a proinflammatory cytokine. A soluble tnfα receptor, etanercept, prevented cancellous bone loss in FcγRIIB −/− mice. our results indicate that FcγRIIB indirectly regulates cancellous bone homeostasis following SLe development. FcγRIIB deletion induces inflammatory bone loss due to increased TNFα-mediated bone resorption without any change in bone formation in mice with SLe-like syndrome.
The involvement of FcγR in bone homeostasis has been studied. Activating, FcγRI, FcγRIIA, FcγRIII and FcγRIV, and inhibitory FcγR, FcγRIIB, are expressed on osteoclasts 9 . Binding of ICs that contain IgG to FcγR results in the activation of macrophages in synovial and cartilage layers. The activating FcγR directly induces severe cartilage destruction, but not bone erosion 10 . Arthritic mice lacking FcγRI/II/III demonstrated an increased level of joint inflammation. It was concluded that the absence of FcγRI/II/III drives joint inflammation, thereby indirectly causing bone resorption. Immunostaining revealed that the amount of RANKL-positive inflammatory cells was higher in the exudate of arthritic knee joints of FcγRI/II/III −/− mice compared to controls. FcγRIV deletion in osteoclasts in a K/BxN serum transfer arthritis model decreased osteoclast differentiation without reducing the clinical signs of arthritis 9 . H-2 b mice deficient in FcγRIIB were susceptible to collagen-induced arthritis after immunization with native type II collagen 11 .
Our previous study indicated that mice with an FcγRIIB deletion resulted in SLE active disease at 6 months old. The FcγRIIB −/− mice had cortical bone loss and decreased mechanical properties at 6 and 10 months old after the development of SLE or lupus disease 12 . The purpose of the present study was to determine the mechanism by which the absence of FcγRIIB affected cancellous bone turnover. Similar to the cortical bone phenotype, no change in cancellous bone volume was observed in 3-month-old FcγRIIB −/− mice. However, 6 and 10 months old FcγRIIB −/− males had cancellous bone loss due to elevated bone resorption without any change in bone formation. Deletion of FcγRIIB decreased cancellous bone volume in 10-, but not 6-month-old female knockouts. Serum TNFα level was increased in FcγRIIB knockouts. Etanercept, a TNFα inhibitor, increased cancellous bone volume and trabecular thickness in FcγRIIB −/− mice. These data suggested that the absence of FcγRIIB induced inflammation and cancellous osteopenia in mice with lupus-like syndrome.
Results
FcγRIIB deletion did not affect cancellous bone in young adult mice. Our previous study indicated that 3-month-old FcγRIIB −/− mice have a normal cortical bone phenotype 12 . To determine whether FcγRIIB deletion affected cancellous bone homeostasis in 3-month-old mice, we examine the skeletal phenotype of 3-monthold FcγRIIB −/− and FcγRIIB +/− males and their WT controls. μCT analysis revealed no difference in cancellous bone volume, trabecular thickness, trabecular number (data not shown), trabecular separation, or SMI between groups (Fig. 1A,B ). Mice deficient in FcγRIIB on a C57BL/6 background developed a lupus-like autoimmunity at 6 months of age as indicated by an increased serum level of anti-dsDNA antibody and spleen B220 low CD138 + plasma cells 12 . Therefore, our results indicated that FcγRIIB deletion did not affect skeletal homeostasis at 3 months of age when SLE disease was not active.
6-and 10-month-old FcγRIIB −/− males had low cancellous bone volume due to increased osteoclast number.
We examined whether the older FcγRIIB −/− mice with active SLE had decreased cancellous bone. The μCT images and analysis of the proximal tibiae in 6-and 10-month-old FcγRIIB −/− males are shown in Fig. 1A ,B, respectively. Cancellous bone volume was decreased by 19% and structural model index was increased by 33% in 6-month-old FcγRIIB −/− males. However, trabecular thickness, trabecular number (data not shown), and trabecular separation were not changed. Ten months old FcγRIIB −/− males had decreased cancellous bone volume and trabecular thickness by 36% and 28%, respectively. Structural model index was decreased by 17%.
Histomorphometric analysis of the femur metaphysis showed a significant decrease in cancellous bone volume at 6 months of age in FcγRIIB −/− males ( Table 1) . Trabecular thickness was decreased in knockouts. However, bone formation parameters, including mineral apposition rate, mineralizing surface, bone formation rate, osteoblast number, osteoid volume and osteoid thickness were not altered ( Table 1 ). In contrast, osteoclast surface per bone surface, osteoclast number per tissue area and osteoclast number per bone perimeter were markedly increased at 6 months of age. Similar to the μCT analysis, the skeletal phenotype was more severe in older mice. FcγRIIB deletion dramatically decreased cancellous bone volume by 48%. Trabecular thickness, and trabecular number were decreased whereas trabecular separation was increased. Osteoclast surface per bone surface and osteoclast number per bone perimeter were increased compared to controls, leading to bone loss in FcγRIIB −/− mice. There was no statistical significant difference between FcγRIIB −/− and control mice in all indices of bone formation at 10 months of age.
FcγRIIB −/− females were osteopenic at 10 months old. To compare the skeletal phenotype observed in females to males, we performed μCT analysis in 6 and 10 months old FcγRIIB −/− females. FcγRIIB −/− females had a normal cancellous bone phenotype at 6 months of age ( Fig. 2A,B ). The μCT analysis indicated that cancellous bone microarchitecture did not change in 6-month-old FcγRIIB −/− females. There was no change in cancellous bone volume, trabecular thickness, trabecular number (data not shown), trabecular separation, or SMI. However, 10-month-old FcγRIIB −/− females were osteopenic ( Fig. 2A,B ). Cancellous bone volume was reduced due to decreased trabecular thickness, however, trabecular number (data not shown), and trabecular separation did not change. The higher SMI was observed in FcγRIIB −/− females compared to WT controls. increased bone resorption in FcγRIIB −/− mice was due to increased osteoclastogenesis.
Histomorphometry indicated that FcγRIIB deletion led to increased osteoclast number without any change in osteoblast number in 6 and 10 months old males. To confirm that this deletion did not affect bone formation, we performed an in vitro assay using primary osteoblasts derived from long bones. ALP and mineralized bone nodules were similar in osteoblasts derived from FcγRIIB −/− mice and their control littermates, indicating that deletion of FcγRIIB did not affect osteoblast differentiation or mineralization (Fig. 3A) .
We determined whether the increased osteoclast number in FcγRIIB −/− mice led to cancellous bone loss. An in vitro osteoclast differentiation assay was performed. Consistent with the increased bone resorption observed in vivo, deletion of FcγRIIB increased TRAP positive osteoclasts derived from bone marrow macrophages (BMMs) of both 6-and 10-month-old mice compared to WT controls (Fig. 3B ). These data revealed the major role of FcγRIIB in osteoclast differentiation subsequent to SLE development.
To investigate whether the presence of FcγRIIB −/− osteoblasts had a role in modulating osteoclast function, osteoblasts derived from FcγRIIB −/− mice and WT controls were co-cultured with BMMs derived from either FcγRIIB −/− mice or WT controls. Osteoclast number was increased when BMMs from FcγRIIB −/− mice were co-cultured with osteoblasts from either FcγRIIB −/− mice or WT ( Fig. 4 ). We observed similar number of osteoclasts generated in co-cultures of WT BMMs with either FcγRIIB −/− or WT osteoblasts. These data revealed that deletion of FcγRIIB in BMMs stimulated osteoclast differentiation. FcγRIIB regulates the expression of bone resorption genes. Deletion of FcγRIIB increased bone resorption without any effect on bone formation in both in vivo and in vitro. The skeletal phenotype was more pronounced in 10-month-old FcγRIIB −/− males. We then selected these mice to determine whether FcγRIIB deletion affected any gene expression. qPCR analysis revealed that osteoblast marker genes, including Alp, type I collagen, Osx, osteopontin, osteocalcin, and Sost expression did not alter ( Fig. 5 ). In contrast, deletion of FcγRIIB increased the mRNA levels for osteoclast marker genes, including Trap, and Ctsk. However, the RANKL/OPG ratio, M-CSF, Nfatc1, Tnfα, c-Fms and IFNγ mRNA levels were not affected in FcγRIIB −/− mice.
FcγRIIB −/− mice produced higher tnfα serum level. To investigate whether the absence of FcγRIIB increased inflammation, the serum levels of proinflammatory cytokines including TNFα, and IL-6 were determined in 6 and 10 months old FcγRIIB −/− males and WT controls. FcγRIIB deletion increased the serum level of TNFα, whereas that of IL-6 was not affected (Fig. 6 ). The higher TNFα serum level was more pronounced in 10compared to 6-month-old FcγRIIB −/− mice. Serum IL-10, a potent anti-inflammatory cytokine, was also measured. We did not observe any change in the serum level of IL-10. We also determined whether the serum TNFα level was altered in 3 months old FcγRIIB −/− males. There was no change in the serum TNFα level in 3-month-old FcγRIIB −/− males compared to WT (5.52 ± 0.16 vs 5.98 ± 0.43 pg/ml). Our data indicated that the serum level of TNFα was increased following SLE development.
tnfα antagonist prevents cancellous bone loss in FcγRIIB −/− mice. We examined whether TNFα is a key factor that induced cancelllous bone loss in FcγRIIB −/− mice. Etanercept, a recombinant human soluble fusion protein of TNFα type II receptor linked to Fc portion of IgG1, was used to block TNFα function. μCT data confirmed that 6-month-old FcγRIIB −/− mice were osteopenic as mentioned earlier ( Fig. 7 ). Inhibition of TNFα increased cancellous bone volume by 49 and 139% in WT and FcγRIIB −/− mice, respectively. SMI was decreased by etanercept treatment in both FcγRIIB −/− mice and WT controls. FcγRIIB −/− mice treated with etanercept had increased trabecular thickness with a concomitant decrease in trabecular separation. Two-way ANOVA indicated no interaction between FcγRIIB deletion and etanercept on any parameter. These findings confirmed that TNFα mediated osteopenia in FcγRIIB −/− mice and that blocking TNFα prevented cancellous bone loss. 
Discussion
SLE is an autoimmune disease characterized by B-cell hyperactivity and B-cell receptor signaling abnormalities. SLE patients have a high prevalence of osteoporotic fracture leading to increased morbidity. The role of FcγRIIB in SLE-associated bone loss is not completely understood. In this study, we determined whether deleting www.nature.com/scientificreports www.nature.com/scientificreports/ FcγRIIB affected cancellous bone phenotype. We found that cancellous bone volume was similar in 3-month-old FcγRIIB −/− mice compared to WT controls. However, FcγRIIB deletion reduced cancellous bone volume at 6 and 10 months old in males. The cancellous osteopenia was associated with increased osteoclast number without any change in osteoblast number. The expressions of Trap and Ctsk, osteoclast marker genes, was upregulated in knockouts. Female FcγRIIB −/− mice had decreased cancellous bone volume at 10, but not 6 months old. Serum TNF-α level, a proinflammatory cytokine, was increased in knockouts. Blocking TNF-α increased cancellous bone volume. Our data suggest that the absence of FcγRIIB results in cancellous bone loss due to inflammation-induced osteoclastic bone resorption in a murine model of spontaneous SLE-like syndrome.
The causes of bone loss in SLE are multifactorial, involving factors intrinsic to the disease itself, adverse effects of medication, and genetic factors. Moreover, proteinuria and renal dysfunction may aggravate vitamin D insufficiency, leading to bone loss in lupus nephritis patients. Low bone mass has an early onset in these patients, most likely due to systemic inflammation-induced increased osteoclastic bone resorption and reduced osteoblastic bone formation. Increased proinflammatory cytokines, including TNFα, IL-1, IL-6, and IL-17 levels might increase the production of RANKL 13 . In addition, activated synovial T cells and fibroblasts express RANKL and www.nature.com/scientificreports www.nature.com/scientificreports/ TNFα to stimulate osteoclast differentiation during inflammation. The inhibition of the BMP/Smad pathway suppresses osteoblast differentiation through activated NF-κB signaling in SLE patients 14 .
Glucocorticoid use is a well-known risk factor for osteoporosis and fracture. However, glucocorticoid-induced osteoporosis in patients with SLE is still controversial. It has been reported that patients recently diagnosed with SLE without glucocorticoid treatment have decreased BMD compared to age-matched healthy individuals 2 . The reduction of BMD is related to decreased serum osteocalcin and increased urinary pyridinoline, suggesting that the disease itself independent of glucocorticoid treatment may lead to bone loss 15 . These findings suggest that glucocorticoids are not the only mechanism responsible for low bone mass in patients with SLE.
Genetic factors contribute to SLE susceptibility and presumably have an important role in determining the etiology of the disease. FcγR regulates autoantibody and IC-induced inflammation. FcγRIIB is expressed on B-cells, mast cells, dendritic cells, neutrophils, macrophages, and osteoclasts 9, 16 . Decreased expression of FcγRIIB on germinal center B-cells was associated with strain-specific susceptibility to autoimmune disease. FcγRIIB −/− mice on the C57BL/6 background spontaneously developed hypergammaglobulinemia, autoimmune glomerulonephritis and IC-mediated SLE-like disease 7 . In contrast, BALB/c mice deficient in FcγRIIB did not develop autoimmunity. This finding confirmed our previous study where FcγRIIB −/− mice on the C57BL/6 background developed SLE at 6 months of age 12 . The serum anti-dsDNA antibody levels and antibody-secreting B220 low CD138 + plasma cells, markers for SLE, were increased in 6-, but not 3-month-old FcγRIIB −/− mice compared to WT controls. FcγRIIB-expressing retrovirus restored tolerance and prevented autoimmune disease in FcγRIIB −/− mice 8 . The inhibitory role of FcγRIIB in the development of autoimmunity is supported by the evidence of SLE-associated FcγRIIB polymorphism in human 17 . In contrast, genetically deleting the activating FcγRs did not develop spontaneous autoimmune diseases in mice 18 . In addition, FcγR deletion did not have any effect on cancellous bone volume and osteoclast number 19 .
Despite extensive studies, genetic factors contributing to the increased bone loss in patients with SLE were not completely understood. The absence of activating FcγRs, FcγRI, FcγRIII or FcγRIV did not affect osteoclast differentiation and bone homeostasis at steady state 9 . No differences in cancellous bone volume, trabecular number, trabecular thickness, trabecular separation, or osteoclast number were observed among strains of knockouts. The role of FcγRI, FcγRIII, and FcγRIV on bone resorption during inflammatory arthritis was investigated. Lack of FcγRIII attenuated arthritis development and decreased inflammatory infiltration and cartilage destruction whereas deletion of FcγRI had no effect on arthritis after transfer of K/BxN serum 20 . FcγRIV-deficient mice had a smaller area of inflammatory infiltrate and bone erosion 9 .
Our studies indicated that the inactivation of FcγRIIB resulted in cancellous osteopenia due to increased osteoclastic bone resorption following SLE development at 6 months of age. These data coincided with the lower lumbar spine and hip BMD in patients with SLE 15, 21 . Ten-month-old FcγRIIB −/− mice had a substantial reduction www.nature.com/scientificreports www.nature.com/scientificreports/ in cancellous bone volume compared to younger mice, suggesting more severe bone loss with longer SLE disease duration. It has been reported that the inhibitory effect of FcγRIIB on osteoclast differentiation was mediated through IgGs 22 . IgG1 has a higher affinity for FcγRIIB and exhibits the strongest level of FcγRIIB-induced negative regulation 3 . The level of IgGs in FcγRIIB −/− mice increased with age 22 . It is possible that the IgGs produced in FcγRIIB −/− mice induces proinflammatory response during autoimmune disease, leading to cancellous bone loss.
Although the relationship between inflammatory cytokines and bone loss in patients with SLE remains unclear, increased osteoclast differentiation induced by proinflammatory cytokines is thought to be the cause of bone resorption in these patients. The inhibitory FcγRIIB is expressed on mast cells and macrophages which have the capacity to trigger strong proinflammatory responses. Patients with SLE are unable to perform IC clearance. These ICs can induce the production of cytokines, including IL-6, TNF-α and IL-10 by macrophages and dendritic cells 23, 24 . Enhanced production of TNF-α in 6-and 10-month-old FcγRIIB −/− mice in our study coincides with the high serum level of TNF-α in the patients with active SLE disease 25 . However, serum IL-6 and IL-10 levels were unaltered. The role of FcγRIIB in the release of proinflammatory mediator was demonstrated by enhanced macrophage responses in FcγRIIB −/− mice with collagen-induced arthritis and IC-mediated alveolitis models 11, 26 . TNF-α antagonist, etanercept, is widely used for the treatment of inflammatory diseases, including rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and plaque psoriasis 27 . Our study indicated that etanercept rescued the skeletal phenotype of FcγRIIB −/− mice, indicating that TNF-α played a major role in cortical and cancellous bone loss in these mice.
MRL/lpr and BXSB/MpJ-Yaa mice are promising models of osteoporosis in murine lupus. It was found that MRL/lpr mice were osteopenic due to decreased bone formation 28 . The BXSB/MpJ-Yaa mice have Yaa mutation on Y chromosome, and male mice therefore develop severe SLE disease. Three months old BXSB/MpJ-Yaa males had a normal skeletal phenotype 29 . But osteopenia developed at 6 months of age. TRAP positive osteoclasts were increased without any change in osteocalcin positive cells, indicating increased bone resorption with normal bone formation. MRL/lpr mice have biphasic increase in circulating level and renal expression of TNF-α 30 . The serum TNF-α level was peak in neonatal mice, normalized by 2 months of age and continuously increased again afterward. The renal TNF-α expression was detected in neonatal mice and dramatically decreased within 2 weeks. However, the expression was increased with progressive lupus nephritis in aged mice. www.nature.com/scientificreports www.nature.com/scientificreports/ Deleting FcγRIIB increased Ctsk and Trap mRNA expression, suggesting elevated bone resorption. In addition to Ctsk's known function in osteoclasts, Ctsk may stimulate bone resorption through immune cell-mediated osteoclast activation. Ctsk deficiency reduced the proinflammatory cytokine expression in rheumatoid arthritis 31 . Trap is essential for skeletal development, bone mineralization, collagen metabolism, and cytokine production by dendritic cells and macrophages. Mice lacking Trap had an osteopetrotic phenotype, reduced resorptive activity during endochondral ossification, premature mineralization of epiphyseal cartilage, and shortened bones 32 .
Taken together, this study establishes the role of FcγRIIB on cancellous bone homeostasis as a link between SLE disease and osteoclast formation. Absence of FcγRIIB induces inflammation by enhancing TNF-α and increases osteoclastic bone resorption, resulting in cancellous bone loss in mice with active SLE disease. Therefore, FcγRIIB is an important candidate as a therapeutic target for autoimmune diseases and osteoporosis. The mice received double fluorochrome labeling with 20 mg/kg calcein (Sigma, St. Louis, MO, USA) to label mineralizing bone. The interlabel periods were 7 and 8 days for 6 and 10 months old FcγRIIB −/− mice and WT controls, respectively. Three-, 6-and 10 months old mice were anesthetized with isoflurane and sacrificed by cervical dislocation. The left tibiae and femurs were fixed in 70% alcohol for microcomputed tomography (μCT) and www.nature.com/scientificreports www.nature.com/scientificreports/ histomorphometric analyses, respectively. The right femurs were removed and kept at −80 °C for RNA isolation and qPCR analysis.
Materials and Methods
For TNF-α inhibitor administration, 6 months old FcγRIIB −/− males and their WT controls were subcutaneously injected with either PBS or 25 mg/kg etanercept (Wyeth, New Jersy, USA) twice a week for 8 weeks. This dose is an intermediate dose for mice 33 . At the end of experiment, left tibiae were removed and fixed in 70% alcohol for μCT analysis µct analysis. µCT was used for nondestructive 3-dimensional evaluation of the bone microarchitecture using a µCT35 scanner (Scanco Medical AG, Bassersdorf, Switzerland) according to standard guidelines 34 . This technique quantitatively assesses cancellous and cortical bone morphology which provides information about the amount of bone. The bone samples were scanned at a voxel size of 7 µm, 50 kVp, 144 µA and 800 ms integration time. The machine was set at a threshold of 220 to distinguish bone from soft tissues. Four hundred and sixty four transverse slices of the cancellous bone at the proximal tibial metaphysis were scanned. Cancellous bone was assessed in 300 transverse slices to determine bone volume (BV/TV, %), trabecular thickness (Tb.Th, mm), trabecular number (Tb.N, /mm), trabecular separation (Tb.Sp, mm), and structural model index (SMI, -).
Histomorphometry. The left femurs were dehydrated in graded acetone, infiltrated and embedded undecal- Osteoblast differentiation. Primary osteoblasts derived from the long bones of FcγRIIB −/− males and their control littermates were prepared as previously described 36 . The cells were cultured in differentiation medium containing α-MEM supplemented with 10% FBS, 100 unit/ml penicillin and 100 μg/ml streptomycin, 10 μM dexamethasone, 5 mM β-glycerophosphate, and 50 μg/ml ascorbic acid. Osteoblasts were fixed with 3.7% formaldehyde, and stained for ALP and mineralized bone nodules with Fast Blue RR (Sigma, St. Louis, MO, USA), and 2% alizarin red (Sigma, St. Louis, MO, USA) on days 7 and 21, respectively. ALP activity was quantified as previously described 37 . Mineralization was measured by extraction of calcified mineral stained with alizarin red using 10% cetylpyridinium chloride in 10 mM sodium phosphate (pH 7) 36 . The concentration of alizarin red (mM) after destaining was determined.
Osteoclast differentiation. Bone marrow cells were cultured in α-MEM containing 10% FBS, 100 unit/ ml penicillin and 100 μg/ml streptomycin for 24 h to obtain BMMs. The BMMs were then cultured on coverslips in α-MEM containing 20 ng/ml M-CSF (R&D Systems, Inc., MN, USA) for 2 days and in the same medium containing 20 ng/ml M-CSF, and 3.3 ng/ml RANKL (R&D Systems, Inc., MN, USA) for an additional 6 days. TRAP-positive spreading osteoclasts containing more than 5 nuclei were quantified using OsteoMeasure software.
For co-culture studies, osteoblasts derived from the long bones of FcγRIIB −/− males and their WT controls were cultured in α-MEM containing 10% FBS, 100 unit/ml penicillin and 100 μg/ml streptomycin for 24 h. BMMs from either FcγRIIB −/− mice or WT controls were added and cultured in α-MEM containing 10 −6 M prostaglandin E 2 (Merck Millipore, Murlington, MA, USA) and 10 −8 M 1,25-dihydroxyvitamin D 3 (Merck Millipore, Murlington, MA, USA) for 4 days. TRAP-positive spreading osteoclasts containing more than 5 nuclei were counted using OsteoMeasure software. qpcR analysis. The right femur distal metaphyses were pulverized in liquid nitrogen. Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The samples were purified using an RNeasy Mini kit (Qiagen, Hilden, Germany). cDNA was synthesized using SuperScript VILO (Invitrogen, Carlsbad, CA, USA). The qPCR was performed at 60 °C for 40 cycles using CFX96 TM Optics Module (Bio-Rad, CA, USA) and GAPDH was used as an internal control for quantification. The primer sequences are listed in Supplementary Table S1 . Serum cytokines. Serum cytokines, TNF-α, IL-6, and IL-10 were measured by ELISA according to the manufacturer's protocol (ThermoFisher Scientific, Waltham, MA, USA).
Statistical analysis.
All data are expressed as mean ± SEM. The unpaired Student's t-test was used to compare the differences between 2 groups. The significance of differences between 3 groups was analyzed using one-way ANOVA followed by Fisher's protected least significant difference test. Interactions between FcγRIIB deletion and etanercept were determined by two-way ANOVA. Differences were defined as significant at p < 0.05.
Data availability
All data are available from the corresponding author upon request.
